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Aims: Many patients with heart failure with preserved ejection fraction (HFpEF) develop 
post-capillary pulmonary hypertension (PH) due to increased left-sided filling pressures. 
However, a subset of patients develops combined post- and pre-capillary PH. We studied the 
value of echocardiographic right-sided characterization for the discrimination between pre- 
versus post-capillary PH in HFpEF, using invasive haemodynamics as gold standard. 
Methods and results: 102 consecutive HFpEF patients with simultaneous right heart 
catheterization and echocardiography were identified. Patients were divided into: ‘no PH’, 
‘isolated post-capillary PH’ and ‘post- and pre-capillary PH’. Systolic pulmonary arterial 
pressure (SPAP), tricuspid valve annular plane systolic excursion (TAPSE), right ventricular-
vascular coupling (TAPSE/SPAP) and VO2-max were assessed. Primary endpoint was all-
cause mortality. A total of 97 patients were included: 22% no PH, 47% isolated post-capillary 
PH and 31% post- and pre-capillary PH. Patients with post- and pre-capillary PH had more 
often diabetes mellitus (47 vs. 24%, p=0.04), had more heart failure hospitalizations (57 vs. 
26%, p=0.007) and lower VO2-max (10 vs. 13 ml/min/kg, p=0.008), compared to those with 
isolated post-capillary PH. Patients with post- and pre-capillary PH also had more reduced 
TAPSE (17 vs. 21 mm, p=0.001) and TAPSE/SPAP (0.3 vs. 0.5, p<0.001). TAPSE/SPAP 
ratio <0.36 had a good accuracy to identify patients with additional pre-capillary PH (C-
statistic 0.86, sensitivity 86% and specificity 79%). TAPSE/SPAP ratio was associated with 
increased mortality (HR 2.51 [95% CI 1.25-5.01], p=0.009). 
Conclusion: Abnormal right ventricular-vascular coupling identifies patients with HFpEF and 
additional pre-capillary PH, and predicts poor outcome in HFpEF. 
 





Heart failure with preserved ejection fraction (HFpEF) is associated with poor outcomes.(1) 
Although the mechanisms behind HFpEF remain incompletely understood, reduced relaxation 
and compliance of the left ventricle (LV) play a dominant role.(2) In a recent meta-analysis, 
we have confirmed that pulmonary hypertension (PH) is common in HFpEF, and that PH-
HFpEF is strongly related to RV failure and death.(3,4) 
The majority of patients with PH-HFpEF have isolated post-capillary PH due to increased 
left-sided filling pressures and resulting pulmonary venous congestion.(5) However, a subset 
of HFpEF patients develops combined post- and pre-capillary PH, characterized by an 
increased pulmonary artery wedge pressure (PAWP) of ≥15 mmHg in combination with an 
elevated diastolic pressure gradient (DPG) and/or increased pulmonary vascular resistance 
(PVR).(6) Genetic predisposition, endothelial dysfunction and neurohormonal activation may 
all explain the development of pre-capillary PH in HFpEF.(6) Characterization of patients 
with additional pre-capillary PH is important, since this group possibly represents a distinct 
subtype within the HFpEF phenotypic spectrum, that might respond to pulmonary vasodilator 
therapy.(7) 
In the present study, we aimed to investigate the clinical characteristics of combined post- and 
pre-capillary PH, and its association with RV failure and death, in patients with HFpEF. We 
then sought to identify non-invasive determinants for the discrimination of pre- versus post-
capillary PH. For this purpose, we investigated HFpEF patients who underwent simultaneous 






This observational cohort study was performed in consecutive outpatients who had a clinical 
diagnosis of HFpEF, based on heart failure symptoms (New York Heart Association [NYHA] 
functional class ≥ II) and LV ejection fraction ≥45%, who had suspected PH based on 
echocardiographic findings, and who were therefore referred for routine left and right-sided 
heart catheterization between October 2011 and September 2014 at our clinic. Patients that 
did not had echocardiography simultaneously with right heart catheterization or patients with 
organic valvular heart disease were excluded. Additional inclusion criteria for the present 
study were LV diastolic dysfunction (E/e’ ≥13 or mean e’ septal and lateral wall <9 cm/s) 
and/or left atrial (LA) dilatation (LA volume index ≥34 ml/m2 or LA parasternal diameter ≥45 
mm) and/or N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) ≥125 
ng/l.(8) The study conforms to the Declaration of Helsinki and the Medical Research 
Involving Human Subjects Act. The institutional review board and local ethic committee 
approved this study. All assessments that were used in the present study were performed in 
the context of regular care and the need for individual informed consent was waived. 
 
Right catheterization protocol 
All patients underwent right heart catheterization performed by a single cardiologist (E.S.H.) 
and simultaneous echocardiography by a single experienced ultrasound technician (Y.M.H.). 
Hemodynamic measurements were performed with patient in fasting state and in supine 
position. The system was zeroed and referenced at patients’ heart level as previously 
described.(9) A 7F thermodilution balloon-tipped catheter was inserted through the femoral 
vein. The catheter was advanced into the right atrium and RV, and subsequently positioned in 
the pulmonary artery and wedge position. Right atrial pressure (RAP), pulmonary artery 
pressures (PAP) and PAWP were recorded at end-expiration. Cardiac output was obtained 
using the Fick equation. Pulmonary vascular resistance, cardiac index, stroke volume, pulse 
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pressure and DPG were calculated using standard formulas. Pulmonary arterial compliance 
was determined as stroke volume / pulse pressure and expressed as ml/mmHg. 
Patients were divided into subgroup: ‘no PH’ (i.e. mean PAP <25 mmHg), isolated post-
capillary PH (i.e. mean PAP ≥25 mmHg, PAWP ≥15 mmHg, DPG <7 mmHg and PVR ≤3.0 
Wood Unit [WU]), combined post- and pre-capillary PH (i.e. mean PAP ≥25 mmHg and 
PAWP ≥15 mmHg with DPG ≥7 mmHg and/or PVR >3.0 WU) and pre-capillary PH (i.e. 
mean PAP ≥25 mmHg and PAWP <15 mmHg).(10) The latter two groups were combined as 
one group with additional pre-capillary PH. 
 
Echocardiographic protocol 
Echocardiographic images were acquired using a Vivid S6 system (General Electric, Horton, 
Norway) with a 2.5- to 3.5-mHz probe. Analyses were performed independently by two 
blinded investigators (T.M.G. and Y.M.H.) using GE EchoPAC version BT12. RV systolic 
function was assessed using multiple parameters. Tricuspid annular plane systolic excursion 
(TAPSE) was obtained in M-mode.(11) In addition, the systolic annular tissue velocity of the 
lateral tricuspid annulus (RV S’) was measured.(11) Furthermore, RV free wall longitudinal 
strain was measured as previously reported, with good inter- and intra-observer 
variability.(12) Finally, RV fractional area change (FAC) was measured using the end-systolic 
and end-diastolic area of the RV in the apical four chamber view.(11) Each parameter for RV 
systolic function was measured in duplicate and averaged. 
Systolic PAP (SPAP) was estimated on echocardiography using the peak velocity of the 
tricuspid regurgitation (TR) jet derived from continuous-wave Doppler. The peak velocity 
was converted to a pressure gradient using the modified Bernoulli equation and was 
subsequently added to an estimation of RAP obtained from the diameter and collapsibility of 
the inferior vena cava (IVC).(11) For an IVC with diameter <2.1 cm that collapses ≥50% with 
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a sniff, the RAP value of 3 mmHg was used, an IVC with diameter ≥2.1 cm that collapses 
<50% suggests RAP of 15 mmHg. If IVC diameter and collapse did not fit this scenario, an 
intermediate value of 8 mmHg was used.(11) Right ventricular-vascular coupling was 
approximated by calculating the ratio of TAPSE to echocardiographic derived SPAP (i.e. 
TAPSE/SPAP).(13) TAPSE/SPAP ratio was validated against TAPSE/SPAP with SPAP 
derived from right heart catheterization. The TAPSE/SPAP ratio was also compared with the 
TAPSE/TR velocity ratio.  
 
Exercise capacity test 
Patients underwent a cardiopulmonary exercise test on a treadmill according to the Weber 
auto protocol. Patients were encouraged to provide a maximum exertion. Stop criteria that 
were considered included: patient reached plateau phase for one minute, patient cannot walk 
further or is unable to maintain walking speed, decrease in breathing reserve and O2 heart rate. 
Reaching the expected VO2 max value was not considered a stop criterion. Peak VO2 was 
expressed in ml/min/kg and as percentage of predicted. 
 
Outcome 
The primary outcome measure was defined as all-cause mortality, ascertained from the 
electronic medical records. 
 
Statistical analyses 
Differences between groups were tested using Independent Samples T-tests for normally 
distributed continuous variables, Mann-Whitney U tests for skewed distributed continuous 
variables and Chi-squared tests for categorical variables. Accuracy for identifying pre-
capillary PH was calculated using C-statistic and by plotting receiver operating characteristic 
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(ROC) curves. Multivariable survival analyses were performed using Cox regression models. 
The maximum number of events per adjustment variable in the logistic regression analysis 
was set at 10, based on previous recommendations.(14) Multicollinearity was tested using 
linear regression. In addition, survival was illustrated in Kaplan-Meier curves and tested using 
log-rank tests. Blant-Altman analysis was performed to analyse agreement between 
TAPSE/SPAP ratio derived from Doppler echocardiography and TAPSE/SPAP obtained from 
right heart catheterization. Statistical significance was considered achieved with p-value 
<0.05. All statistical analyses were performed using SPSS (Version 22, 2013).  
 
RESULTS 
A total of 102 HFpEF patients with suspected PH on a previous echocardiography who were 
referred for right heart catheterization were identified. Four patients who did not had a 
simultaneous echocardiography. Thus in total, 97 patients were included in the present 
analysis. Seventy-six patients (78.4%) had PH, defined as mean PAP ≥25 mmHg (Table 1). 
Of these, 46 (47.4%) had isolated post-capillary PH, 24 patients (24.7%) had combined post- 
and pre-capillary PH, and six patients (6.2%) had isolated pre-capillary PH according to the 
diagnostic definition. Fourteen patients (14%) did not undergo a conclusive exercise capacity 
test. In 79 (81.4%) patient, tricuspid regurgitation jet was sufficient to estimate SPAP. 
Patients with PH-HFpEF were more symptomatic (i.e. higher NYHA functional class, more 
diuretic use and reduced exercise capacity), compared to patients without PH (Table 1). 
Permanent atrial fibrillation was also more prevalent in PH-HFpEF (43 versus 5%, p=0.004). 
 
Characteristics of pre- versus post-capillary PH in HFpEF 
As seen in Table 1, PAWP was comparable between patients with isolated  post-capillary PH 
and additional pre-capillary PH. However, patients with additional pre-capillary PH had more 
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often diabetes mellitus, and there was a trend that these patients more often had chronic 
obstructive pulmonary disease (COPD). HFpEF patients with pre-capillary PH had the highest 
NT-proBNP levels, were more often previously hospitalized for heart failure, and had the 
lowest exercise capacity. RV function and TAPSE/SPAP ratio was lower in patients with a 
pre-capillary component of PH, compared to isolated post-capillary PH. 
Individual data of the six patients with isolated pre-capillary PH are depicted in 
Supplementary Table 1. Four of these patients had COPD, three had diabetes mellitus and 
PVR ranged from 5.3 to 9.3 WU. 
 
Outcome of pre- versus post-capillary PH in HFpEF 
During a median follow-up of 816 (547 – 1047) days, 20 patients (20.6%) died. The results of 
the Cox regression model for the prediction of death are depicted in Table 2. In univariable 
analyses, diabetes mellitus, COPD, RV function, TAPSE/TR velocity and TAPSE/SPAP 
ratio, PAP, PVR and the presence of additional pre-capillary PH were all associated with 
mortality. The presence of PH per se was not associated with increased mortality. RV 
function according to TAPSE, RV S’ and FAC remained associated with mortality after 
adjustment of age and sex. Also reduced TAPSE/SPAP ratio remained associated with death 
after adjustment for age and sex (Table 2), and after adjustment for diabetes mellitus and 
COPD (Supplementary Table 2). There was multicollinearity between TAPSE/SPAP ratio 
and other established echocardiographic measurements of RV function and with invasive 
pulmonary pressures (Supplementary Table 2). 
 
Identification of pre- versus post-capillary PH in HFpEF 
The results of the C-statistics to discriminate between isolated post-capillary PH and 
additional pre-capillary PH are depicted in Table 3. The non-invasively derived 
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TAPSE/SPAP ratio had a C-statistic of 0.86. The ROC-analysis for TAPSE/SPAP ratio 
demonstrates a good accuracy for the prediction of any pre-capillary PH in HFpEF, with a 
sensitivity of 87% and specificity of 79% for TAPSE/SPAP 0.36 (Figure 1). Figure 2 
illustrates the survival curve when patients were divided according to TAPSE/SPAP ratio 
<0.36 (Log-rank p=0.006). In Table 3 in the Supplementary Material, baseline 
characteristics are presented when patients were divided according to TAPSE/SPAP <0.36. 
Patients with low TAPSE/SPAP ratio had a higher prevalence of atrial fibrillation, more 
previous HF hospitalizations, higher PAP and PVR, lower pulmonary arterial compliance, 
more LV diastolic dysfunction, lower peak VO2-max and higher NT-proBNP.  
In a sub analysis, after exclusion of the six patients with isolated pre-capillary PH, 
echocardiographic TAPSE/SPAP ratio remained predictive of mortality, after adjustment for 
age and sex: HR 2.25 per standard deviation decrease (95% CI 1.09-4.67), p=0.029 and Log-
rank p=0.036 for TAPSE/SPAP <0.36. 
The non-invasive TAPSE/SPAP ratio correlated strongly with the invasively derived 
TAPSE/SPAP ratio (r=0.71, p<0.001), (Supplementary Figure). Blant-Altman analysis for 
the comparison between TAPSE/SPAP derived from right heart catheterization and from 
echocardiography is also illustrated in the Supplementary Figure. 
 
DISCUSSION 
In our study of HFpEF patients undergoing simultaneous right heart catheterization and 
echocardiography, we found that patients with a pre-capillary component of PH had 
significantly lower exercise capacity and were more at risk for RV failure, HF hospitalizations 
and death, compared to HFpEF patients without pre-capillary PH. Abnormal right ventricular-
vascular coupling (i.e. reduced TAPSE/SPAP ratio) identified these HFpEF patients with a 
pre-capillary component of PH, and predicted poor outcomes. 
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It is increasingly evident that both PH and RV dysfunction are of major importance in 
HFpEF, given their high prevalence and strong association with adverse prognosis.(3) The 
development of additional pre-capillary PH in HFpEF is of particular concern given its strong 
prognostic impact.(7) Identification of pre-capillary PH in HFpEF also potentially opens the 
door to the pulmonary vasculature as a potential treatment target in patients with PH-HFpEF, 
but currently no drugs that are approved for the treatment of pulmonary arterial hypertension 
(group 1 PH) have been proven safe and beneficial in patients with PH-HFpEF.(7) Hence, in 
the latest European Society of Cardiology Guidelines for the Diagnosis and Treatment of PH, 
the use of such therapies has a class III recommendation for patients with PH due to left heart 
disease (group 2 PH).(10) There are currently several on-going trials with other specific drugs 
to treat PH-HFpEF, including riociguat (NCT02744339), vericiguat (NCT01951638) and 
nitrite (NCT02742129). 
 
Characteristics of pre- versus post-capillary PH in HFpEF 
The present patient cohort was rigorously screened for HFpEF according to the current 
recommendations. We observed that 31% of the HFpEF patients referred for catheterization 
had a pre-capillary component of PH, of which six patients had isolated pre-capillary PH, 
with a PAWP less than 15 mmHg. One might argue whether the latter are true HFpEF 
patients. Although patients are divided into different PH groups by definition of 
hemodynamic measurements, LV filling pressures in HFpEF might be <15 mmHg at resting 
conditions, since filling pressures are highly variable over time and are also influenced by 
volume status and physical activity.(15) In those patients, LV filling pressures may typically 
rise with exercise.(16) Thus, HFpEF patients with optimal diuretic dose may demonstrate 
temporally lower or only borderline elevated LV filling pressures at rest, while mean PAP 
remains high in the setting of secondary vasculopathy. In the absence of invasive 
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haemodynamics during exercise, we cannot exclude that some of these patients might still be 
misclassified as HFpEF. However, based on the current diagnostic work-up for HFpEF – in 
which echocardiography still is the first line bedside tool – our patients clearly had HFpEF 
according to the current definition. In the present study, none of the patients were on 
pulmonary vasodilator therapy at the time of hemodynamic assessment. 
We did observe a trend that COPD was more prevalent in patients with (additional) pre-
capillary PH. COPD is a common finding in HFpEF, with a previously reported prevalence 
rate of 24% in multiple HFpEF studies.(3) We have to keep in mind that the diagnostic 
evaluation between COPD and HFpEF is challenging, since both patient groups may share 
signs and symptoms (e.g. dyspnea on exertion), the presence of a “preserved” LVEF, and the 
strong association with PH.(10) Therefore, one should be aware of an overlap between both 
diseases and the present study demonstrates the need for hemodynamic testing in these 
patients, to better discriminate between group 2 and 3 PH. 
Patients with a pre-capillary component of PH-HFpEF were characterized by severely 
depressed exercise capacity. The reduced exercise capacity in patients with pre-capillary PH 
could therefore be relate to reduced pulmonary vascular function, higher pulmonary pressures 
and resulting impaired RV function, which was clearly demonstrated in the combined post- 
and pre-capillary PH group. Recently, the prognostic value of tricuspid regurgitation recorded 
during exercise was demonstrated in HFpEF, which was independent of LV diastolic 
dysfunction.(17) Interestingly, Borlaug et al. also noticed that patients with HFpEF displayed 
impaired RV reserve with exercise, even in the early stages of the disease, suggesting the 
importance of biventricular dysfunction in HFpEF.(16)  
Another characteristic of patients with additional pre-capillary PH was the presence of 
diabetes mellitus. This finding is consistent with a prior invasive study of HFpEF with pre-
capillary PH, in which the presence of comorbidities distinguished these patients from those 
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with idiopathic pulmonary arterial hypertension.(18) This suggests that the development of 
pre-capillary PH in HFpEF is not solely the result of chronic backward transmission of left-
sided filling pressures, but that other mechanisms might play a role. Indeed the multi-hit 
hypothesis, wherein endothelial dysfunction and systemic inflammation driven by a 
combination of comorbidities (such as diabetes and COPD), has been postulated to contribute 
to pulmonary vascular remodelling in HFpEF.(19)  
 
Identification of pre- versus post-capillary PH in HFpEF 
The present study described the important value of pre-capillary PH in HFpEF. The definition 
of pre-capillary PH hinges on invasively derived measurements. However, it is rather 
impractical to routinely perform right heart catheterizations in all HFpEF patients.  
RV afterload is predominantly determined by increased PVR and elevated PAP.(20) 
However, since RV function is highly sensitive to alterations in afterload,(21) it has recently 
been suggested that characterization of RV function in HFpEF may be best framed in relation 
to prevailing RV load.(22) The relationship of RV function to afterload (i.e. right ventricular-
vascular coupling) and cardiovascular outcome has been established for both PAH and heart 
failure.(13,23) In the present study, we demonstrated that the non-invasive TAPSE/SPAP 
ratio <0.36 has a strong prognostic value and is also useful in discriminating HFpEF patients 
with additional pre-capillary PH from HFpEF patients without pre-capillary PH. While 
TAPSE/SPAP does not directly measure pulmonary vascular resistance, our results show that 
the presence of abnormal right ventricular-vascular coupling (reflected by the TAPSE/SPAP 
ratio) increased the probability that the patient may have a pre-capillary component of PH, 
although further verification is required. TAPSE/SPAP ratio may also be used as an endpoint 
in trials targeting PH-HFpEF. 
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We observed that patients with low TAPSE/SPAP ratio displayed some distinct 
characteristics, such as higher prevalence of atrial fibrillation, more severe LV diastolic 
dysfunction and higher NT-proBNP, compared with patients with higher TAPSE/SPAP ratio. 
This finding is perhaps an indication of more advance staged heart failure in those patients 
with low right ventricular-vascular coupling. In a recent sub analysis from the RELAX trial, 
Hussain et al. demonstrated similar findings. In their study, HFpEF patients with RV 
dysfunction and impaired right ventricular-vascular coupling also seemed to have more 
advanced heart failure.(22) 
 
Limitations 
Some limitations merit emphasis. First, patients with HFpEF and suspected PH on previous 
echocardiography were clinically referred for right heart catheterization and this might have 
introduced a selection bias. Second, the haemodynamic assessment was only performed at 
resting condition. Especially when the diagnosis of HFpEF is uncertain, as was the case for 
the six patients with PAWP <15 mmHg, availability of LV filling pressures obtained during 
exercise would have abled use to better discriminate between group 2 PH and other PH 
groups. In addition, the sample size was small and the study was also not powered to 
investigate multivariate associations with outcome using >2 adjustment variables. 
Furthermore, despite the high correlation with the invasively derived TAPSE/SPAP ratio, the 
non-invasive assessment of TAPSE/SPAP, measured with Doppler echocardiography, could 
only be assessed in those patients with sufficient tricuspid regurgitation, which may have 





Patients with HFpEF and an important pre-capillary component of PH are at increased risk for 
RV failure and death, compared to patients with HFpEF without additional pre-capillary PH. 
Impaired right ventricular-vascular coupling (reflected by reduced TAPSE/SPAP ratio) 
suggests more advanced heart failure and identifies these vulnerable HFpEF patients with 
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Table 1: Baseline characteristics of the total study population and subgroups 

















Demographics       
Age (years) 70.8±8.1 74.5±8.8 0.09 74.7±7.3 74.2±10.8 0.83 
Male sex 7 (33%) 23 (30%) 0.79 11 (24%) 12 (40%) 0.14 
Body mass index (kg/m
2
) 27.5±4.7 28.7±6.0 0.39 28.1±5.8 29.6±6.3 0.29 
Comorbidities       
Hypertension 14 (67%) 50 (66%) 0.94 31 (67%) 19 (63%) 0.72 
Coronary artery disease 7 (33%) 26 (34%) 0.94 14 (30%) 12 (40%) 0.39 
Atrial fibrillation   0.004   0.17 
Paroxysmal 5 (24%) 10 (13%)  7 (15%) 3 (10%)  
Permanent 1 (5%) 33 (43%)  16 (35%) 17 (57%)  
Diabetes mellitus 6 (29%) 25 (33%) 0.71 11 (24%) 14 (47%) 0.04 
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COPD 3 (14%) 13 (17%) 0.76 5 (11%) 8 (27%) 0.07 
Heart failure characteristics       
NYHA functional class   <0.001   0.17 
II 17 (81%) 22 (29%)  16 (35%) 6 (20%)  
III 4 (19%) 54 (71%)  30 (65%) 24 (80%)  
Diuretics use 13 (62%) 62 (82%) 0.04 37 (80%) 25 (83%) 0.52 
Previous HF hospitalization 4 (19%) 29 (38%) 0.10 12 (26%) 17 (57%) 0.007 
Haemodynamics       
Heart rate (bpm) 67±14 72±12 0.07 72±11 73±14 0.65 
Systolic blood pressure (mmHg) 149±23 150±25 0.93 155±21 141±28 0.02 
Diastolic blood pressure 
(mmHg) 
66±16 70±12 0.16 71±13 69±11 0.41 
Cardiac output (l/min) 6.6±2.0 5.4±1.2 0.01 5.8±1.2 4.7±1.1 <0.001 
Cardiac index (l/min/m
2
) 3.6±1.0 2.8±0.7 <0.001 3.1±0.6 2.5±0.6 <0.001 
Mean PAWP (mmHg) 10±3 19±5 <0.001 20±4 18±6 0.09 
Systolic PAP (mmHg) 31±6 55±14 <0.001 49±9 64±16 <0.001 
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Diastolic PAP (mmHg) 11±3 20±6 <0.001 18±4 24±6 <0.001 
Mean PAP (mmHg) 18±3 35±8 <0.001 31±5 41±9 <0.001 
Mean RAP (mmHg) 4±3 10±5 <0.001 8±4 11±5 0.005 
PVR (WU) 1.3±0.4 3.1±2.1 <0.001 1.9±0.6 4.9±2.3 <0.001 
PAC (ml/mmHg) 5.4±1.9 2.4±1.0 <0.001 2.8±0.8 1.9±1.0 <0.001 
Echocardiography       
LV ejection fraction (%) 57±5 57±5 0.72 57±5 56±5 0.29 
LV mass index (kg/m
2
) 101±27 94±31 0.38 91±35 99±25 0.28 
E/e’ 11.8 [8.3-14.1] 12.7 [10.1-16.5] 0.12 12.1 [9.9-15.5] 14.4 [10.1-21.4] 0.20 
Mean e’ septal/lateral wall 7.8 [6.2-8.7] 7.5 [6.2-8.9] 0.90 7.6 [6.5-9.6] 7.0 [4.9-8.5] 0.12 
LAVi (ml/m
2
) 42±18 48±16 0.18 49±18 47±14 0.67 
TAPSE (mm) 22.9±6.1 19.6±4.8 0.01 21.2±4.5 17.1±4.3 0.001 
RV S’ (cm/s) 9.6±2.4 9.1±2.8 0.56 9.9±2.7 7.7±2.4 0.001 
FWLS (%) -21.5±6.2 -19.9±5.7 0.32 -21.8±5.7 -17.5±4.9 0.004 
FAC (%) 51±12 45±13 0.13 50±11 39±12 <0.001 
TR velocity (m/s) (n=79) 2.7±0.4 3.2±0.5 0.003 3.0±0.4 3.5±0.6 0.001 
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TAPSE/TR velocity ratio (n=74) 2.6±0.7 1.8±0.3 0.01 1.8±0.3 1.3±0.3 <0.001 
TAPSE/SPAP ratio* (n=74) 0.4±0.2 0.4±0.2 0.01 0.5±0.2 0.3±0.1 <0.001 
Exercise capacity (n=83)       
Peak VO2-max (ml/min/kg) 14.8±3.5 11.6±3.6 0.001 12.5±3.8 10.1±2.8 0.008 
Peak VO2-max of predicted (%) 70±17 60±18 0.04 65±18 51±15 0.003 
Laboratory test       
NT-proBNP (ng/l) 486 [216-1233] 1087 [497-2021] 0.01 840 [425-1816] 1548 [701-2340] 0.04 
Data is reported as mean ± standard deviation, median [interquartile range] and n (%). COPD chronic obstructive pulmonary disease; FAC fractional area change; FWLS free 
wall longitudinal strain; HF heart failure; LAVi left atrial volume index; NT-proBNP N-terminal prohormone of brain natriuretic peptide; NYHA New York Heart 
Association; PAC pulmonary arterial compliance; PAP pulmonary arterial pressure; PAWP pulmonary artery wedge pressure; PH pulmonary hypertension; PVR pulmonary 
vascular resistance; RAP right atrial pressure; RV S’ systolic annular tissue velocity of the lateral tricuspid annulus; SPAP systolic pulmonary artery pressure; TAPSE 




Table 2: Cox regression model for the prediction of death in HFpEF 
 Unadjusted HR p-value Adjusted HR* p-value 
Age 1.02 (0.97-1.08) 0.41   
Male sex 0.83 (0.30-2.31) 0.73   
Body mass index 0.98 (0.91-1.06) 0.98   
Coronary artery disease 2.23 (0.91-5.48) 0.08   
Atrial fibrillation 1.51 (0.62-3.65) 0.36   
Diabetes mellitus 3.58 (1.46-8.77) 0.005 3.66 (1.48-9.06) 0.005 
COPD 3.71 (1.49-9.24) 0.005 3.64 (1.43-9.26) 0.007 
TAPSEǂ 1.78 (1.05-3.01) 0.03 1.81 (1.06-3.08) 0.03 
RV S’ǂ 2.45 (1.34-4.48) 0.001 2.65 (1.43-4.92) 0.002 
FWLS† 1.55 (0.96-2.50) 0.07   
FACǂ 2.13 (1.33-3.40) 0.001 2.20 (1.35 (3.60) 0.002 
TR velocity 1.42 (0.95-2.12) 0.09   
TAPSE/TR velocity ratioǂ 2.16 (1.17-3.97) 0.01 2.19 (1.17-4.09) 0.01 
TAPSE/SPAP ratio*ǂ 2.42 (1.24-4.70) 0.003 2.51 (1.25-5.01) 0.009 
Mean PAWP† 0.81 (0.51-1.30) 0.38   
Systolic PAP† 1.44 (1.05-1.98) 0.03 1.78 (1.16-2.73) 0.008 
Mean PAP† 1.46 (1.03-2.08) 0.03 1.85 (1.15-2.99) 0.01 
Cardiac index 1.36 (0.85-2.16) 0.20   
PVR† 1.52 (1.14-2.03) 0.004 1.72 (1.24-2.38) 0.001 
PACǂ 1.81 (0.99-3.30) 0.05   
PH versus no-PH 1.49 (0.43-5.10) 0.53   
Pre- versus post-capillary PH 3.91 (1.37-11.11) 0.01 4.35 (1.51-12.54) 0.006 
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Same abbreviations as in Table 1. *Echocardiographic derived TAPSE/SPAP. †Per standard deviation increase; 
ǂper standard deviation decrease. The multivariable analysis was adjusted for age and sex.  
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Table 3: C-statistic of the identification of pre-capillary PH in HFpEF 
Variable C-statistic 
Mean PAP 0.91 
PAC 0.86 
Systolic PAP 0.86 
TAPSE/SPAP ratio* 0.86 
Cardiac index 0.79 
FAC 0.77 
TAPSE 0.76 
Peak VO2-max % of predicted 0.76 
RV S’ 0.73 
Mean RAP 0.73 
FWLS 0.70 
TAPSE/TR velocity ratio 0.69 
NT-proBNP 0.68 
TR velocity 0.66 
Diabetes mellitus 0.61 
Age 0.57 
Male sex 0.57 
COPD 0.57 






Figure 1: Receiver operating characteristic curve for identification of pre-capillary 
pulmonary hypertension. TAPSE/SPAP ratio 0.36 had a sensitivity of 86% and specificity 





Figure 2: Kaplan-Meier survival curve for the prediction of death. 
 
